Short answer
Xenon Pharmaceuticals Inc. (XENE) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$110M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$110M
- −21.5% YoY · +0.3% QoQ
- EPS (diluted)
- −$1.10
- +4.3% YoY · +0.9% QoQ
Source: XBRL data from the Xenon Pharmaceuticals Inc. (XENE) Q3 2026 10-Q on SEC EDGAR. USD.
Xenon Pharmaceuticals Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales
- Quarterly loss before taxes $108.6M vs $90.2M YoY, R&D expenses $95.6M vs $77.1M
- Azetukalner worst cost driver: R&D $54.5M, up $11.8M YoY
- Cash and securities $1,153.5M at September 30, 2026, supported by $843.3M financing inflows
- Operating cash outflow $274.6M for nine months, up from $197.6M YoY; funding expected for at least 12 months
Risk Factors
- Newly triggered regulatory risk: azetukalner NDA submission to FDA in September 2026
- Clinical-development risk: voluntary pause on new enrollment in Phase 3 MDD and BPD studies announced in September
- Financial risk: $323.5 million nine-month net loss and $1,568.9 million accumulated deficit
- Liquidity risk: $1,153.5 million cash and marketable securities expected to fund operations for at least 12 months
- Currency risk: unhedged Canadian-dollar exposure, including CAD$57.5 million in cash and marketable securities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xenon Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.